ACRS logo

Aclaris Therapeutics (ACRS) Cash From Operations

Annual CFO

-$78.33 M
-$10.76 M-15.92%

December 31, 2023

Summary

Performance

1-Year Change

-15.92%

3-Year Change

-102.74%

5-Year Change

+22.31%

15-Year Change

-43.29%

ACRS Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

18.39%
ACRS annual cash flow from operations is higher than 18.39% of companies in Healthcare sector

High & Low

All-time High

-$4.92 M

3-Year Low

-$78.33 M
ACRS annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ACRS previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 27, 2025
ACRS next annual earnings announcement is scheduled for Feb 27, 2025

OtherACRScash flowmetrics:

Annual CFI

$46.22 M
ACRS annual cash flow from investing activities is $46.22 million

Annual CFF

$26.71 M
ACRS annual cash flow from financing activities is $26.71 million

Annual FCF

-$79.63 M
ACRS annual free cash flow is -$79.63 million

Annual CAPEX

$1.31 M
ACRS annual capital expenditures is $1.31 million

Quarterly CFO

$22.00 M
+$34.32 M+278.54%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+189.59%

3-Year Change

+307.43%

5-Year Change

+194.18%

ACRS Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

85.21%
ACRS quarterly cash flow from operations is higher than 85.21% of companies in Healthcare sector

High & Low

All-time High

$22.00 M
ACRS quarterly cash flow from operations is currently at an all-time high

3-Year Low

-$26.35 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ACRS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
ACRS next earnings announcement is scheduled for Feb 27, 2025

OtherACRScash flowmetrics:

Quarterly CFI

$2.79 M
ACRS quarterly cash flow from investing activities is $2.79 million

Quarterly CFF

$22.00 K
ACRS quarterly cash flow from financing activities is $22.00 thousand

Quarterly FCF

$22.00 M
ACRS quarterly free cash flow is $22.00 million

Quarterly CAPEX

$0.00
ACRS quarterly capital expenditures is $0.00

TTM CFO

-$17.90 M
+$46.56 M+72.23%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+80.26%

3-Year Change

+59.24%

5-Year Change

+75.12%

ACRS TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

47.71%
ACRS TTM cash flow from operations is higher than 47.71% of companies in Healthcare sector

High & Low

All-time High

-$2.80 M

3-Year Low

-$90.68 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ACRS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
ACRS next earnings announcement is scheduled for Feb 27, 2025

OtherACRScash flowmetrics:

TTM CFI

$26.50 M
ACRS TTM cash flow from investing activities is $26.50 million

TTM CFF

$5000.00
ACRS TTM cash flow from financing activities is $5000.00

TTM FCF

-$18.46 M
ACRS TTM free cash flow is -$18.46 million

TTM CAPEX

$562.00 K
ACRS TTM capital expenditures is $562.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ACRS Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-15.9%+189.6%+80.3%
3 y3 years-102.7%+307.4%+59.2%
5 y5 years+22.3%+194.2%+75.1%

ACRS Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-50.2%at lowat high+183.5%at high+80.3%
5 y5-year-102.7%+18.8%at high+183.5%at high+81.4%
alltimeall time-1492.0%+22.3%at high+170.3%-538.8%+83.8%

Aclaris Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
$22.00 M(-278.5%)
-$17.90 M(-72.2%)
Jun 2024
-
-$12.32 M(-40.8%)
-$64.45 M(-11.4%)
Mar 2024
-
-$20.82 M(+207.9%)
-$72.79 M(-7.1%)
Dec 2023
-$78.33 M(+15.9%)
-$6.76 M(-72.5%)
-$78.33 M(-13.6%)
Sep 2023
-
-$24.56 M(+18.9%)
-$90.68 M(+22.6%)
Jun 2023
-
-$20.65 M(-21.6%)
-$73.94 M(+1.4%)
Mar 2023
-
-$26.35 M(+37.9%)
-$72.95 M(+8.0%)
Dec 2022
-$67.57 M(+29.6%)
-$19.11 M(+144.5%)
-$67.57 M(+3.1%)
Sep 2022
-
-$7.82 M(-60.3%)
-$65.53 M(-4.1%)
Jun 2022
-
-$19.67 M(-6.2%)
-$68.32 M(+12.2%)
Mar 2022
-
-$20.97 M(+22.8%)
-$60.87 M(+16.8%)
Dec 2021
-$52.13 M(+34.9%)
-$17.07 M(+61.0%)
-$52.13 M(+18.7%)
Sep 2021
-
-$10.61 M(-13.2%)
-$43.92 M(-3.4%)
Jun 2021
-
-$12.22 M(-0.1%)
-$45.46 M(+3.2%)
Mar 2021
-
-$12.23 M(+38.1%)
-$44.06 M(+14.0%)
Dec 2020
-$38.63 M(-59.9%)
-$8.86 M(-27.1%)
-$38.63 M(-23.0%)
Sep 2020
-
-$12.15 M(+12.3%)
-$50.17 M(-18.3%)
Jun 2020
-
-$10.82 M(+59.0%)
-$61.38 M(-14.7%)
Mar 2020
-
-$6.80 M(-66.6%)
-$71.93 M(-25.4%)
Dec 2019
-$96.44 M
-$20.39 M(-12.7%)
-$96.44 M(-6.6%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$23.36 M(+9.3%)
-$103.30 M(-5.9%)
Jun 2019
-
-$21.38 M(-31.7%)
-$109.80 M(-0.4%)
Mar 2019
-
-$31.32 M(+14.9%)
-$110.26 M(+9.4%)
Dec 2018
-$100.81 M(+84.4%)
-$27.25 M(-8.7%)
-$100.81 M(+9.8%)
Sep 2018
-
-$29.86 M(+36.8%)
-$91.77 M(+21.3%)
Jun 2018
-
-$21.83 M(-0.2%)
-$75.63 M(+18.4%)
Mar 2018
-
-$21.87 M(+20.1%)
-$63.88 M(+16.9%)
Dec 2017
-$54.66 M(+58.0%)
-$18.21 M(+32.8%)
-$54.66 M(+22.8%)
Sep 2017
-
-$13.71 M(+36.1%)
-$44.52 M(+9.4%)
Jun 2017
-
-$10.08 M(-20.4%)
-$40.72 M(+0.9%)
Mar 2017
-
-$12.66 M(+56.8%)
-$40.37 M(+16.7%)
Dec 2016
-$34.60 M(+69.9%)
-$8.07 M(-18.5%)
-$34.60 M(+12.8%)
Sep 2016
-
-$9.90 M(+1.8%)
-$30.67 M(-2.1%)
Jun 2016
-
-$9.73 M(+41.2%)
-$31.33 M(+28.1%)
Mar 2016
-
-$6.89 M(+66.6%)
-$24.46 M(+20.1%)
Dec 2015
-$20.37 M(+166.7%)
-$4.14 M(-60.9%)
-$20.37 M(+25.5%)
Sep 2015
-
-$10.57 M(+269.3%)
-$16.23 M(+186.6%)
Jun 2015
-
-$2.86 M(+2.1%)
-$5.66 M(+102.1%)
Mar 2015
-
-$2.80 M
-$2.80 M
Dec 2014
-$7.64 M(+55.2%)
-
-
Dec 2013
-$4.92 M
-
-

FAQ

  • What is Aclaris Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Aclaris Therapeutics?
  • What is Aclaris Therapeutics annual CFO year-on-year change?
  • What is Aclaris Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Aclaris Therapeutics?
  • What is Aclaris Therapeutics quarterly CFO year-on-year change?
  • What is Aclaris Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Aclaris Therapeutics?
  • What is Aclaris Therapeutics TTM CFO year-on-year change?

What is Aclaris Therapeutics annual cash flow from operations?

The current annual CFO of ACRS is -$78.33 M

What is the all time high annual CFO for Aclaris Therapeutics?

Aclaris Therapeutics all-time high annual cash flow from operations is -$4.92 M

What is Aclaris Therapeutics annual CFO year-on-year change?

Over the past year, ACRS annual cash flow from operations has changed by -$10.76 M (-15.92%)

What is Aclaris Therapeutics quarterly cash flow from operations?

The current quarterly CFO of ACRS is $22.00 M

What is the all time high quarterly CFO for Aclaris Therapeutics?

Aclaris Therapeutics all-time high quarterly cash flow from operations is $22.00 M

What is Aclaris Therapeutics quarterly CFO year-on-year change?

Over the past year, ACRS quarterly cash flow from operations has changed by +$46.56 M (+189.59%)

What is Aclaris Therapeutics TTM cash flow from operations?

The current TTM CFO of ACRS is -$17.90 M

What is the all time high TTM CFO for Aclaris Therapeutics?

Aclaris Therapeutics all-time high TTM cash flow from operations is -$2.80 M

What is Aclaris Therapeutics TTM CFO year-on-year change?

Over the past year, ACRS TTM cash flow from operations has changed by +$72.78 M (+80.26%)